Swiss pharmaceutical company Novartis AG says it plans to invest $500 million in Russia over a five-year period. Novartis says the investment will include the construction of a drug production plant in the city of St. Petersburg.
Sanofi-aventis will be granted a research and development license to Merck's MEKI inhibitor MSC1936369B to assess safety and initial clinical activity in combination with its PI3K inhibitor SAR245408.
Health organizations will undergo a strategy makeover in 2011 as they react to new rules and payment models, continuing cost pressures and new customer demands, according to the Top Health Industry Issues of 2011.
Bayer HealthCare Pharmaceuticals, Inc. announced the U.S. Food and Drug Administration has approved a new oral contraceptive, SAFYRAL. SAFYRAL raises folate levels for the purpose of reducing the risk of rare neural tube defects.
Bristol-Myers Squibb has reached an agreement that could be worth up to $286 million to buy exclusive worldwide rights to develop, make and sell a potential HIV treatment in mid-stage testing by Oncolys BioPharma Inc.
Consumer products company Prestige Brands Holdings Inc. said it is buying Johnson & Johnson's U.S. Dramamine business for $76 million in cash in a move to expand its over-the-counter brands.
AstraZeneca said the Food and Drug Administration has again extended its review of the experimental blood thinner Brilinta, the second delay this year for one of the company's potential blockbuster products.
Mylan Inc. confirmed that it has been sued by Shionogi Pharma Inc. and Cima Labs Inc. over an application filed with the Food and Drug Administration to make a generic version of Orapred, a steroid used to reduce inflammation in asthma and other conditions.
Carl Zeiss, a provider of microscopy solutions for research, clinical, and industrial applications, introduces a new generation of ergonomic and compact tissue culture microscopes with its Primo Vert Monitor.
Sapio Sciences has announced that Mitomics has selected Exemplar LIMS as its Laboratory Information Management solution. Sapio was chosen because of its experience in rapidly implementing CLIA compliant LIMS.
Thermo Fisher Scientific Inc. announced the launch of its Sorvall RC BIOS centrifuge system for high-speed, high-volume batch bioprocessing applications.
BD Biosciences announced the latest round of winners of its Research Grant Program. An independent panel of distinguished scientists selected the winners and the recipients will each receive a $10,000 grant of research reagents.
Affymetrix, Inc. announced that a judge has granted the company’s motion for summary judgment that Affymetrix does not infringe the patents held by Illumina, Inc. and has directed that the patent infringement lawsuits brought against it be closed.
A newly published insight into the biology of many kinds of less-aggressive but still lethal brain tumors, or gliomas, opens up a wide array of possibilities for new therapies, according to scientists.
New findings indicate that compounds called oxysterols are not present in any significant amount in multiple sclerosis patients, contradicting a previous study that suggested that some of these cholesterol metabolites were associated with MS.